Summary: Researchers cracked a critical hidden mechanism behind the “heart-brain axis,” revealing how a heart attack physically reshapes brain function to cause depression, anxiety, and cognitive decline. The research demonstrates that following a cardiac event, a highly reactive, toxic byproduct called methylglyoxal (MG) surges into the bloodstream and aggregates inside mood and memory centers of the brain.
This discovery explains the biological link between cardiac stress and post-stroke psychiatric conditions while introducing an innovative peptide therapy designed to trap the toxin and shield vulnerable brain tissue.
Key Facts
- The Heart-Brain Axis: Neurological and cognitive conditions that manifest after a heart attack are directly fueled by specific, cascading molecular alterations kicked off by structural damage to heart tissue.
- The Toxic Byproduct Accumulation: Following a myocardial infarction, the human body enters a state of high metabolic stress characterized by oxygen drops and systemic inflammation. This hostile shift causes methylglyoxal (MG)—a reactive molecule famously studied in metabolic disorders like diabetes—to spike in the blood and pool in brain zones governing cognition and emotion.
- The Psychological Trap: Individuals recovering from a heart attack experience depression and anxiety at a rate up to three times higher than the general population. Alarmingly, cardiac patients who develop these mental health conditions are up to 2.7 times more likely to suffer a subsequent, fatal heart attack or death.
- Unveiling Chronic Risks: By establishing methylglyoxal as a primary instigator of cellular brain damage and localized chronic neuroinflammation, this study uncovers a distinct biological pathway explaining why a heart attack spikes long-term dementia risks.
- The MG-Trapping Peptide: Moving rapidly from raw discovery to targeted clinical therapeutics, the University of Ottawa team has engineered a unique peptide therapeutic engineered to physically trap methylglyoxal before it can damage neural cells.
- Dual-System Protection: Senior author Dr. Erik Suuronen notes that if forthcoming clinical trials prove successful, this trapping therapy will do more than preserve brain health; by alleviating depression and anxiety, it could drastically lower the 2.7x risk of repeat cardiac mortality, filling a massive unmet clinical gap.
Source: University of Ottawa
A new study led by a team from the University of Ottawa takes a major step forward in understanding how a heart attack can dramatically reshape brain function and trigger neurological effects, from depression and anxiety to different types of cognitive decline.
This ‘heart-brain axis’ concept suggests that neurological conditions following a heart attack could be driven in part by molecular changes set in motion by damage to the heart. While there are many factors and signaling pathways involved in heart-brain interactions, this newly published research suggests that a toxic byproduct produced by the body plays a major role in the brain following a heart attack.
Brain inflammation after cardiac events
At the center of the discovery is methylglyoxal (MG), a highly reactive molecule, which surges in the bloodstream and accumulates in the brain following a heart attack. Following a heart attack, the body enters a state of stress—oxygen drops, inflammation rises, metabolism shifts—causing MG levels to surge in the bloodstream and then accumulate in the brain in specific brain regions linked to mood and cognition.
The occurrence of depression and anxiety in heart attack patients is up to three times higher than the general population, with patients who suffer depression or anxiety may be up to 2.7 times more likely to experience another heart attack or death.
Charting new territory in brain-heart connection
Published in the journal Advanced Sciences, this finding could potentially transform recovery and long-term outcomes for millions as it reshapes how scientists understand long-term risks after myocardial infarction and explain why emotional and cognitive disorders are so common after cardiac events.
“Methylglyoxal has been widely studied for its role in metabolic diseases, including diabetes, but much less is known about its function in other diseases. In a previous study, we discovered that methylglyoxal was produced by dying heart tissue after a heart attack (…) based on this evidence, we predicted that methylglyoxal in the blood would target other organs and tissues, including the brain—and this is what we did indeed observe,” says senior author Dr. Erik Suuronen, a Full Professor in the Faculty of Medicine’s Department of Surgery, a scientist in the Division of Cardiac Surgery and director of its BEaTs Research Program at the University of Ottawa Heart Institute.
Moving from discovery toward therapy
The team’s discoveries raise important questions about neurodegenerative disease as chronic inflammation and cellular damage in the brain are key drivers of cognitive conditions like dementia.
By identifying methylglyoxal as a trigger, this research suggests a new pathway through which heart attacks could increase long-term neurological risk. Having identified methylglyoxal as a potential target for treating neurological disorders after a heart attack, the next step is to explore how MG-driven inflammation leads to neuron death and mental health conditions.
Importantly, the research team has already developed a peptide therapeutic that can trap methylglyoxal and prevent it from damaging cells.
“This therapy will soon be tested to see if it can protect the brain from damage after a heart attack,” says Dr. Suuronen, who believes if successful, such treatments could do more than protect brain function; they could potentially reduce the risk of future cardiac events.
“Given the increased risk of subsequent heart attacks or death in heart attack patients who experience depression or anxiety, being able to alleviate these conditions could reduce subsequent major cardiac events and improve the lives of countless patients, filling an urgent unmet clinical need,” Dr. Suuronen adds.
Key Questions Answered:
A: For decades, it was assumed to be purely psychological trauma, but this study proves a major physical, toxic link. When heart tissue dies during a heart attack, it pumps out a highly reactive, toxic byproduct called methylglyoxal (MG). This toxin travels through the bloodstream and pools inside the brain’s emotional and memory centers, triggering cellular damage and inflammation that degrades brain health.
A: The heart-brain axis is a two-way street. Once the toxic MG surge damages brain cells and triggers chronic mental health struggles, those psychiatric conditions feed straight back into your cardiovascular system. The persistent stress of anxiety and depression strains the heart, raising the likelihood of a secondary, fatal heart attack or death by 2.7 times.
A: Think of it like a molecular sponge. The University of Ottawa team developed a custom peptide therapeutic specifically engineered to recognize, latch onto, and neutralize methylglyoxal in the body. By trapping this molecule before it can infiltrate the central nervous system, the drug prevents it from damaging brain tissue, shielding both your mental health and your long-term cognitive survival.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurology research news
Author: Paul Logothetis
Source: University of Ottawa
Contact: Paul Logothetis – University of Ottawa
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Methylglyoxal Accumulation is Associated with Brain Inflammation after Myocardial Infarction with Sex and Regional Differences” by Ramis Ileri, Xixi Guo, Erik J. Suuronen. Advanced Science
DOI:10.1002/advs.202522584
Abstract
Methylglyoxal Accumulation is Associated with Brain Inflammation after Myocardial Infarction with Sex and Regional Differences
Patients with myocardial infarction (MI) have an increased risk of developing neurological disease and cognitive impairment, but the mechanisms underlying the heart-brain interaction remain to be better elucidated.
Methylglyoxal (MG), a highly reactive dicarbonyl, is a shared causative factor associated with cardiovascular and neurological diseases. MG-derived advanced glycation end products (MG-AGEs) accumulate in the heart and circulation post-MI, making it a promising target in studying the heart-brain axis.
Here, we report that MG-AGEs accumulate in the mouse brain at 6 h and 7 days post-MI, with the highest expression observed in the brainstem, followed by the cortex. Notably, males had higher MG-AGE expression compared to females in most brain regions.
The accumulation of MG-AGEs in the brain was correlated with increased neuroinflammation, including a greater number of activated microglia and macrophages, and increased expression of AGE receptors.
Greater inflammatory factor expression (NF-κB and TNF-α) and a reduction in tight junction proteins of the blood brain barrier were also observed.
Taken together, this study reveals a novel MG-mediated mechanism with sex-based differences that may contribute significantly to heart-brain interactions after MI and identifies a promising therapeutic target for treating the neurological impairment associated with heart disease.
